# Phase 2 colonic cancer trials recruiting: 59 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 59 trials in phase 2 for colonic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 colonic cancer trials: 59 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/colonic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 59
- Recruiting or not yet: 59
- Read on: November 19, 2026

## Trials

The 25 newest of 59, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07904130 | Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer | West China Hospital | Phase 2 | Not yet recruiting | Colo-rectal Cancer | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904130) |
| October 27, 2026 | NCT07896681 | Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Colorectal Cancer (CRC) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896681) |
| September 25, 2026 | NCT07841236 | ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer | Fudan University | Phase 2 | Recruiting | Colon Cancer, Deficient Mismatch Repair, Microsatellite Instability-High (MSI-H) | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841236) |
| September 25, 2026 | NCT07840677 | Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Recruiting | Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840677) |
| September 16, 2026 | NCT07823322 | A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After... | Incyte Corporation | Phase 2 | Recruiting | CRC (Colorectal Cancer) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823322) |
| September 8, 2026 | NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | Solstice Oncology, Inc. | Phase 2 | Recruiting | Colon Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808151) |
| July 23, 2026 | NCT07722754 | Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial | Guangdong Provincial People's Hospital | Phase 2 | Recruiting | Colorectal Neoplasms Malignant, Neoplasm, Metastatic | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722754) |
| July 9, 2026 | NCT07691489 | A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691489) |
| June 16, 2026 | NCT07649473 | QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm... | Fujian Medical University | Phase 2 | Not yet recruiting | Colon Cancer, Synchronous Liver Metastases | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649473) |
| May 19, 2026 | NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 | City of Hope Medical Center | Phase 2 | Recruiting | Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IIB Colon... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07595874) |
| April 24, 2026 | NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Colon Cancer (Stage II &Amp; III), Immunotherapy, Beta Blocker, Neoadjuvant Chemoimmunotherapy | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549906) |
| April 7, 2026 | NCT07515963 | FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. | Zhongnan Hospital | Phase 2 | Not yet recruiting | Colo-rectal Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515963) |
| April 6, 2026 | NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) | Korea University Anam Hospital | Phase 2 | Not yet recruiting | Colon Cancer | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510932) |
| March 12, 2026 | NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Recruiting | Colon Adenocarcinoma | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07468630) |
| February 13, 2026 | NCT07409844 | Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab, Immunotherapy | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409844) |
| February 12, 2026 | NCT07407465 | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | Gruppo Oncologico del Nord-Ovest | Phase 2 | Recruiting | Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07407465) |
| February 12, 2026 | NCT07405476 | Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment | Emory University | Phase 2 | Recruiting | Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC... | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405476) |
| December 12, 2025 | NCT07279077 | Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A... | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 | Recruiting | Colon Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiation Therapy | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07279077) |
| November 3, 2025 | NCT07224022 | Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Colon Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07224022) |
| October 31, 2025 | NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular... | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223424) |
| September 17, 2025 | NCT07178717 | A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients... | Vall d'Hebron Institute of Oncology | Phase 2 | Recruiting | Colo-rectal Cancer | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178717) |
| September 5, 2025 | NCT07156682 | QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer | Qilu Hospital of Shandong University | Phase 2 | Not yet recruiting | Colon Cancer, MSS/pMMR, QL1706 | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07156682) |
| August 25, 2025 | NCT07140679 | Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | Emory University | Phase 2 | Recruiting | Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140679) |
| July 25, 2025 | NCT07085169 | Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC | Ruijin Hospital | Phase 2 | Recruiting | Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, Bevacizumab | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085169) |
| July 10, 2025 | NCT07058012 | A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in... | NSABP Foundation Inc | Phase 2 | Recruiting | Colo-rectal Cancer | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07058012) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 6 |
| Sun Yat-sen University | 3 |
| City of Hope Medical Center | 3 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 3 |
| West China Hospital | 2 |
| Emory University | 2 |
| Ruijin Hospital | 2 |
| Peking University | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| NSABP Foundation Inc | 1 |
| The First Affiliated Hospital of Zhengzhou University | 1 |
| Qilu Hospital of Shandong University | 1 |
| Vall d'Hebron Institute of Oncology | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| Affiliated Hospital of Nantong University | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Universitaire Ziekenhuizen KU Leuven | 1 |
| Solstice Oncology, Inc. | 1 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 1 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 1 |
| Zhongnan Hospital | 1 |
| Centre Hospitalier Universitaire de Besancon | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| SCRI Development Innovations, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 22 |
| United States | 16 |
| Spain | 5 |
| Italy | 4 |
| France | 4 |
| Denmark | 3 |
| Belgium | 3 |
| United Kingdom | 3 |
| Netherlands | 2 |
| Puerto Rico | 1 |
| Germany | 1 |
| Sweden | 1 |
| Slovenia | 1 |
| Australia | 1 |
| Canada | 1 |
| Hungary | 1 |
| Russia | 1 |
| Singapore | 1 |
| Taiwan | 1 |
| Japan | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Engineering firms in the United States](https://specstream.ai/data/businesses/engineering-firms/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Hospital equipment suppliers in the United States](https://specstream.ai/data/businesses/hospital-equipment-suppliers/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
